Wim Dokter
Chief Scientific Officer Byondis B.V.
Seminars
Wednesday 14th October 2026
Presentation Preview: Spotlighting Comprehensive Preclinical Development of Antifolate ADCs to Enter IND Phase for a Novel Drug-Linker Mechanism
- Presenting development of a novel antifolate drug-linker platform, leveraging a toxin class with a clinically validated mechanism of action
- Exploring in vitro and in vivo preclinical development and physicochemical properties of frontrunner antifolate ADC program
- Laying out pharmacology studies and dose range finding investigation in the lead up to antifolate ADC IND studies
